2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. Carbonic Anhydrase Isoform
  6. Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Inhibitors (124):

Cat. No. Product Name Effect Purity
  • HY-13650
    Indisulam
    		Inhibitor 99.80%
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
  • HY-B1480
    Ethoxzolamide
    		Inhibitor 99.85%
    Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
  • HY-N0639
    Punicalin
    		Inhibitor 99.89%
    Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.
  • HY-B1424
    Benzthiazide
    		Inhibitor 99.70%
    Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells.
  • HY-B0782A
    Acetazolamide sodium
    		Inhibitor 99.66%
    Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.
  • HY-32933
    4-Acetylphenylboronic acid
    		Inhibitor 99.96%
    4-Acetylphenylboronic acid is a potent inhibitor of carbonic anhydrases II(CA II), with IC50s of 246 μM and 281.40 μM for bovine CA II (bCA II) and human CA II (hCA II), respectively.
  • HY-120677
    AHR-15010
    		Inhibitor
    AHR-15010 is an oral active carbonic anhydrase inhibitor with the IC50 of 0.13 μM. AHR-15010 shows anti-arthritic activity and can be used for study of arthritis .
  • HY-19213
    L-693612
    		Inhibitor
    L-693612 (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
  • HY-B0397
    Dichlorphenamide
    		Inhibitor 98.90%
    Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.
  • HY-118467
    Benzolamide
    		Inhibitor 99.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
  • HY-B0483
    Tioxolone
    		Inhibitor 98.24%
    Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
  • HY-163109
    Carbonic anhydrase inhibitor 16
    		Inhibitor 98.00%
    Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (Ki: 28.5 nM, 2.2 nM).
  • HY-N0085
    Dimethylfraxetin
    		Inhibitor 99.97%
    Dimethylfraxetin is a Carbonic anhydrase inhibitor, with a Ki value of 0.0097 μM.
  • HY-108316
    Sultiame
    		Inhibitor 99.76%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
  • HY-W074975
    CL 5343
    		Inhibitor ≥98.0%
    CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells.
  • HY-148135
    hCAI/II-IN-6
    		Inhibitor ≥98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
  • HY-B0782S
    Acetazolamide-d3
    		Inhibitor 99.95%
    Acetazolamide-d3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.
  • HY-B0109
    Dorzolamide
    		Inhibitor
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-B0124A
    Zonisamide sodium
    		Inhibitor
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
  • HY-B0124S
    Zonisamide-d4
    		Inhibitor 99.38%
    Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].